{
  "_metadata": {
    "version": "2.0",
    "target": "B7-H3",
    "last_updated": "2026-02-04"
  },
  "target": {
    "name": "B7-H3",
    "full_name": "B7 homolog 3 protein",
    "aliases": ["CD276", "B7H3", "4Ig-B7-H3"],
    "gene_symbol": "CD276",
    "target_type": "immune checkpoint"
  },
  "investment_thesis": {
    "headline": "B7-H3 is the leading next-gen ADC target with $22B Merck deal and limited normal tissue expression",
    "key_points": [
      "Ideal ADC target: High tumor expression, minimal normal tissue expression",
      "Merck mega-deal: $22B collaboration with Daiichi Sankyo for I-DXd",
      "Multiple modalities: ADCs, CAR-T, bispecifics, radioconjugates all in development",
      "Best clinical data: 52% ORR in ES-SCLC with ifinatamab deruxtecan",
      "Regulatory momentum: BTD and ODD designations for lead programs"
    ],
    "full_text": "B7-H3 (CD276) is emerging as the premier target for next-generation oncology therapeutics, particularly antibody-drug conjugates. The immune checkpoint protein is highly expressed across multiple solid tumors (lung, prostate, breast, pediatric cancers) while showing minimal expression on normal tissues - making it an ideal target for cytotoxic payloads.\n\nThe Merck-Daiichi Sankyo $22B collaboration (October 2023) represents the largest ADC deal in history, validating the target's commercial potential. Lead asset ifinatamab deruxtecan (I-DXd, DS-7300) has shown impressive efficacy with 52% ORR in extensive-stage small cell lung cancer and is advancing through registrational trials.\n\nThe competitive landscape includes multiple modalities: ADCs from GSK, BioNTech, and Chinese biotechs; CAR-T programs from academic centers; bispecifics from MacroGenics; and the only approved radioconjugate omburtamab for CNS tumors. This diversity suggests confidence in the target across the industry."
  },
  "mechanism": {
    "biology": "B7-H3 is an immune checkpoint protein that inhibits T-cell activation and promotes tumor immune evasion. It is overexpressed in >70% of solid tumors.",
    "rationale": "High tumor expression + low normal tissue expression = ideal therapeutic window for ADCs. The DXd payload has proven efficacy with Enhertu.",
    "unique_value": "Unlike PD-L1 or HER2, B7-H3 is broadly expressed across tumor types with minimal toxicity concerns."
  },
  "market_opportunity": {
    "total_market": "$80B+ oncology biologics market",
    "target_share": "$5-10B peak revenue potential for best-in-class B7-H3 ADC",
    "patient_population": "Broad applicability: SCLC, NSCLC, prostate, breast, pediatric tumors",
    "unmet_need": "ES-SCLC has no targeted therapies; 2L+ solid tumors need new options"
  },
  "key_risks": [
    {
      "risk": "Competition from other ADC targets (TROP2, HER3, etc.)",
      "severity": "Medium",
      "mitigation": "B7-H3 expression is broader and more consistent than alternatives"
    },
    {
      "risk": "Merck/Daiichi dominance may crowd out other players",
      "severity": "High",
      "mitigation": "Differentiation through indication focus or modality"
    }
  ],
  "catalysts": [
    {
      "event": "TROPION-Lung08 Phase 3 readout (NSCLC)",
      "timing": "H2 2025",
      "drug": "Ifinatamab deruxtecan",
      "significance": "High"
    },
    {
      "event": "Potential accelerated approval in ES-SCLC",
      "timing": "2025",
      "drug": "Ifinatamab deruxtecan",
      "significance": "High"
    },
    {
      "event": "BLA decision for omburtamab (CNS tumors)",
      "timing": "2024",
      "drug": "Omburtamab",
      "significance": "High"
    }
  ],
  "assets": [
    {
      "name": "Ifinatamab deruxtecan",
      "code_names": ["DS-7300", "I-DXd", "DS-7300a"],
      "target": "B7-H3",
      "modality": "ADC",
      "modality_detail": "Topoisomerase I inhibitor (DXd/deruxtecan payload)",
      "payload": "DXd (deruxtecan)",
      "owner": "Daiichi Sankyo",
      "partner": "Merck",
      "phase": "Phase 3",
      "status": "Active",
      "lead_indication": "ES-SCLC (Extensive-Stage Small Cell Lung Cancer)",
      "other_indications": ["NSCLC", "Solid tumors", "Breast cancer", "Prostate cancer"],
      "regulatory": {"btd": true, "odd": true, "fast_track": true, "prime": false},
      "deal": {
        "headline": "Merck-Daiichi Sankyo collaboration",
        "upfront": 4000,
        "equity": 1500,
        "milestones": 16500,
        "date": "2023-10",
        "partner": "Merck",
        "territory": "Global (co-develop/co-commercialize)",
        "notes": "Includes I-DXd + 2 other Daiichi ADCs. Largest ADC deal ever."
      },
      "key_data": "52% ORR in ES-SCLC; 26% ORR in heavily pretreated solid tumors (ASCO 2024)",
      "differentiator": "Best-in-class DXd payload; deep Merck partnership; most advanced"
    },
    {
      "name": "Risvutatug rezetecan",
      "code_names": ["HS-20093", "GSK4428859"],
      "target": "B7-H3",
      "modality": "ADC",
      "modality_detail": "Topoisomerase I inhibitor payload",
      "owner": "Hansoh Pharma",
      "partner": "GSK",
      "phase": "Phase 3",
      "status": "Active",
      "lead_indication": "ES-SCLC",
      "other_indications": ["NSCLC", "Solid tumors"],
      "regulatory": {"btd": false, "odd": false, "fast_track": true, "prime": false},
      "deal": {
        "headline": "GSK collaboration",
        "upfront": 85,
        "milestones": 1525,
        "date": "2024-01",
        "partner": "GSK",
        "territory": "Ex-China rights"
      },
      "key_data": "75% ORR in ES-SCLC 2L+ (WCLC 2023); durable responses",
      "differentiator": "Chinese-origin ADC with strong efficacy data; GSK global development"
    },
    {
      "name": "YL201",
      "code_names": ["YL201"],
      "target": "B7-H3",
      "modality": "ADC",
      "owner": "MediLink Therapeutics",
      "phase": "Phase 2",
      "status": "Active",
      "lead_indication": "ES-SCLC",
      "key_data": "61% ORR in ES-SCLC; 80.6% DCR (ASCO 2024)",
      "differentiator": "Competitive China ADC with strong Phase 1/2 data"
    },
    {
      "name": "DB-1311",
      "code_names": ["DB-1311", "BNT324"],
      "target": "B7-H3",
      "modality": "ADC",
      "owner": "DualityBio",
      "partner": "BioNTech",
      "phase": "Phase 1/2",
      "status": "Active",
      "lead_indication": "Solid tumors",
      "deal": {
        "headline": "BioNTech collaboration",
        "upfront": 170,
        "milestones": 1500,
        "date": "2024-03",
        "partner": "BioNTech",
        "territory": "Global ex-Greater China"
      },
      "differentiator": "BioNTech partnership; mRNA combo potential"
    },
    {
      "name": "Vobramitamab duocarmazine",
      "code_names": ["MGC018"],
      "target": "B7-H3",
      "modality": "ADC",
      "modality_detail": "Duocarmazine DNA alkylating payload",
      "payload": "Duocarmazine",
      "owner": "MacroGenics",
      "phase": "Phase 2",
      "status": "Active",
      "lead_indication": "mCRPC (Metastatic Castration-Resistant Prostate Cancer)",
      "other_indications": ["Solid tumors", "NSCLC", "Triple-negative breast cancer"],
      "key_data": "40% PSA50 response rate in mCRPC; differentiated prostate focus",
      "differentiator": "Only B7-H3 ADC with duocarmazine payload; prostate cancer focus"
    },
    {
      "name": "Omburtamab",
      "code_names": ["8H9", "Burtomab"],
      "target": "B7-H3",
      "modality": "Radioconjugate",
      "modality_detail": "Iodine-131 labeled monoclonal antibody (radioimmunotherapy)",
      "payload": "Iodine-131",
      "owner": "Y-mAbs Therapeutics",
      "phase": "Filed",
      "status": "Active",
      "lead_indication": "CNS/leptomeningeal metastases from neuroblastoma",
      "other_indications": ["Medulloblastoma", "DIPG", "Brain metastases"],
      "regulatory": {"btd": true, "odd": true, "fast_track": false, "prime": true, "rmat": true},
      "key_data": "BLA filed Oct 2022; PDUFA extended; Phase 3 for DIPG",
      "differentiator": "Only radioconjugate; CNS penetration; pediatric focus"
    },
    {
      "name": "Enoblituzumab",
      "code_names": ["MGA271"],
      "target": "B7-H3",
      "modality": "mAb",
      "modality_detail": "Fc-enhanced humanized IgG1 monoclonal antibody",
      "owner": "MacroGenics",
      "phase": "Phase 2",
      "status": "Active",
      "lead_indication": "HNSCC",
      "other_indications": ["Prostate cancer", "Pediatric solid tumors", "Melanoma"],
      "regulatory": {"btd": false, "odd": true, "fast_track": false, "prime": false},
      "key_data": "Fc-enhanced for ADCC; combination with retifanlimab (PD-1)",
      "differentiator": "Fc-enhanced ADCC; IO combination approach"
    },
    {
      "name": "MGD024",
      "code_names": ["MGD024"],
      "target": "B7-H3 x CD3",
      "modality": "Bispecific",
      "modality_detail": "DART (Dual-Affinity Re-Targeting) B7-H3 x CD3 bispecific",
      "owner": "MacroGenics",
      "phase": "Phase 1",
      "status": "Active",
      "lead_indication": "Solid tumors",
      "other_indications": ["Pediatric solid tumors"],
      "regulatory": {"btd": false, "odd": true, "fast_track": false, "prime": false},
      "differentiator": "DART platform; T-cell engagement"
    },
    {
      "name": "4SCAR-276 (Stanford B7-H3 CAR-T)",
      "code_names": ["4SCAR-276"],
      "target": "B7-H3",
      "modality": "CAR-T",
      "modality_detail": "4th generation CAR-T targeting B7-H3",
      "owner": "Stanford University",
      "phase": "Phase 1",
      "status": "Active",
      "lead_indication": "Pediatric solid tumors",
      "other_indications": ["Neuroblastoma", "Osteosarcoma"],
      "regulatory": {"btd": false, "odd": true, "fast_track": false, "prime": false},
      "differentiator": "Academic; pediatric focus; 4th gen CAR"
    },
    {
      "name": "SCRI-CARB7H3 (Seattle CAR-T)",
      "code_names": ["SCRI-CARB7H3"],
      "target": "B7-H3",
      "modality": "CAR-T",
      "modality_detail": "CAR-T for CNS tumors with intrathecal delivery",
      "owner": "Seattle Children's Research Institute",
      "phase": "Phase 1",
      "status": "Active",
      "lead_indication": "Medulloblastoma",
      "other_indications": ["DIPG", "CNS tumors", "Ependymoma"],
      "key_data": "Intrathecal delivery for CNS penetration",
      "differentiator": "CNS administration; pediatric CNS tumors"
    }
  ],
  "efficacy_comparison": [
    {
      "drug": "Ifinatamab deruxtecan (DS-7300)",
      "trial": "Phase 1/2",
      "phase": "Phase 1/2",
      "dose": "8 mg/kg Q3W",
      "endpoint": "ORR",
      "result": 52,
      "placebo": 0,
      "placebo_adjusted": 52,
      "indication": "ES-SCLC",
      "source": "ASCO 2024",
      "notes": "Best-in-class response rate"
    },
    {
      "drug": "HS-20093 (GSK)",
      "trial": "Phase 1/2",
      "phase": "Phase 1/2",
      "dose": "Dose escalation",
      "endpoint": "ORR",
      "result": 75,
      "placebo": 0,
      "placebo_adjusted": 75,
      "indication": "ES-SCLC 2L+",
      "source": "WCLC 2023",
      "notes": "Impressive early data from Chinese program"
    }
  ],
  "investment_metrics": {
    "total_committed": 5755,
    "total_potential": 23780,
    "largest_deal": {
      "name": "Ifinatamab deruxtecan (Merck/Daiichi)",
      "committed": 5500,
      "potential": 22000,
      "partner": "Merck"
    },
    "assets_with_deals": 4,
    "phase_3_assets": 2,
    "total_assets": 23
  }
}
